ArticleNano letters2018
Modifying a Commonly Expressed Endocytic Receptor Retargets Nanoparticles in Vivo.
Article in Nano letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Lipid nanoparticle screening in nonhuman primates with minimal loss of life.Nature biotechnology · 2026Article
- Endo/Lysosomal-Escapable Lipid Nanoparticle Platforms for Enhancing mRNA Delivery in Cancer Therapy.Pharmaceutics · 2025Review
- Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses.Nature communications · 2025Article
- Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Silver Nanoparticles (AgNPs) Uptake by Caveolae-Dependent Endocytosis is Responsible for Their Selective Effect Towards Castration Resistant Prostate Cancer.International journal of nanomedicine · 2024Article
- Nanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery.Nature chemistry · 2023Article
- The Transcriptional Response to Lung-Targeting Lipid NanoparticlesNano letters · 2023Article
- Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review.Clinical pharmacology : advances and applications · 2023Review
- Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo.Nature communications · 2022Article
- Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery.Nature nanotechnology · 2022Article
- Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics.Drug metabolism and pharmacokinetics · 2022Review
- Drug delivery systems for RNA therapeutics.Nature reviews. Genetics · 2022Review
- Performance of nanoparticles for biomedical applications: TheBiophysics reviews · 2022Review
- Therapeutic RNA Delivery for COVID and Other Diseases.Advanced healthcare materials · 2021Review
- Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine.Chemical Society reviews · 2021Review
- Non-Viral Targeted Nucleic Acid Delivery: Apply Sequences for Optimization.Pharmaceutics · 2020Review
- Treating Cystic Fibrosis with mRNA and CRISPR.Human gene therapy · 2020Review
- Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands.Bioengineering & translational medicine · 2020Article
- Increased PIP3 activity blocks nanoparticle mRNA delivery.Science advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nanoparticles are often targeted to receptors expressed on specific cells, but few receptors are (i) highly expressed on one cell type and (ii) involved in endocytosis. One unexplored alternative is manipulating an endocytic gene expressed on multiple cell types; an ideal gene would inhibit delivery to cell type A more than cell type B, promoting delivery to cell type B. This would require a commonly expressed endocytic gene to alter nanoparticle delivery in a cell type-dependent manner in vivo; whether this can occur is unknown. Based on its microenvironmental regulation, we hypothesized Caveolin 1 (Cav1) would exert cell type-specific effects on nanoparticle delivery. Fluorescence was not sensitive enough to investigate this question, and as a result, we designed a platform named QUANT to study nanoparticle biodistribution. QUANT is 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.